A rare case of septic pulmonary embolism in co-existence with infective endocarditis and COVID-19

Ozdemir Y. E., Demir A. S., Ozdemir M. S., Mavi B., Ozen C., Karaosmanoglu H. K.

FUTURE VIROLOGY, vol.17, no.10, pp.711-716, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 10
  • Publication Date: 2022
  • Doi Number: 10.2217/fvl-2022-0029
  • Journal Name: FUTURE VIROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE
  • Page Numbers: pp.711-716
  • Keywords: anticoagulant therapy, COVID-19, infective endocarditis, methicillin sensitive Staphylococcus aureus, septic pulmonary embolism, STAPHYLOCOCCUS-AUREUS, DIAGNOSIS, THERAPY
  • Istanbul University-Cerrahpasa Affiliated: Yes

Abstract

Infective endocarditis (IE) symptoms including fever, fatigue, dyspnea and myalgia are similar in COVID-19 findings. Therefore, the diagnosis of IE may be missed in patients with COVID-19. Co-existence with IE in COVID-19 is rarely reported. However, to our knowledge, only one case of septic pulmonary embolism in COVID-19 and IE was reported. Here, we describe a case of septic embolism due to tricuspid endocarditis caused by intravenous drug use in patients with COVID-19. In this fatal case, the use of prophylactic anticoagulants due to COVID-19 probably caused the tendency to hemorrhagic cerebrovascular complications. Our report emphasizes the complexity of anticoagulant prophylaxis in patients with COVID-19 which may cause hypercoagulopathy in co-existence with IE.